-
Cipla Q3 PAT rises 21% to Rs 842 crore
Pharmaceutical major Cipla on Thursday reported a 21 per cent rise in its consolidated net profit to Rs 842 crore for the quarter ended December 31, 2023, helped by strong growth in the domestic market.
-
Cipla launches generic version of Merck's Keytruda in India
Cipla has launched the generic version of Merck's blockbuster cancer drug Keytruda (pembrolizumab) in India, making it the first company to offer a biosimilar version of the drug in the country.
-
Cipla to acquire majority stake in Ethicare Remedies
Cipla has entered into an agreement to acquire a majority stake in Ethicare Remedies, a leading player in the respiratory segment in India, for Rs 2,300 crore.
-
Cipla ties up with Kitsol Healthcare to market respiratory portfolio in Chile
Cipla has entered into an exclusive marketing and distribution alliance with Kitsol Healthcare Ltda to market Cipla’s respiratory portfolio in Chile.
-
Cipla launches nasal spray for allergic rhinitis in India
Cipla has launched Nasoclear-AQ nasal spray, a once-daily intranasal spray indicated for the treatment of allergic rhinitis in India.
-
Cipla partners with Arcturus Therapeutics to develop mRNA-based therapies
Cipla has entered into a strategic partnership with Arcturus Therapeutics to develop and commercialize mRNA-based therapies for infectious diseases and other therapeutic areas.
-
Cipla acquires exclusive rights to market and distribute InvaGen Pharmaceuticals’ portfolio in India
Cipla has acquired the exclusive rights to market and distribute InvaGen Pharmaceuticals’ portfolio of differentiated and branded generic injectable products in India.
-
Cipla reports strong financial results for Q3 FY23
Cipla has reported strong financial results for the third quarter of fiscal year 2023, with revenue growing by 13% year-over-year and net profit increasing by 17%.